董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stefano Buono | 男 | Director and Chief Executive Officer | 50 | 未披露 | 未持股 | 2017-03-29 |
| Christian Merle | 男 | Director | 63 | 未披露 | 未持股 | 2017-03-29 |
| Leopoldo Zambeletti | 男 | Director | 48 | 未披露 | 未持股 | 2017-03-29 |
| Kapil Dhingra | 男 | Director | 57 | 未披露 | 未持股 | 2017-03-29 |
| Francois Nader | 男 | Director | 60 | 未披露 | 未持股 | 2017-03-29 |
| Claudio Costamagna | 男 | Chairman | 60 | 未披露 | 未持股 | 2017-03-29 |
| Steve Gannon | 男 | Director | 55 | 未披露 | 未持股 | 2017-03-29 |
| Yvonne Greenstreet | 女 | Director | 54 | 未披露 | 未持股 | 2017-03-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stefano Buono | 男 | Director and Chief Executive Officer | 50 | 未披露 | 未持股 | 2017-03-29 |
| Heinz Mausli | 男 | Chief Financial Officer | 53 | 未披露 | 未持股 | 2017-03-29 |
| Gerard Ber | 男 | Chief Operating Officer | 58 | 未披露 | 未持股 | 2017-03-29 |
| Claude Hariton | 男 | Global Head of R&D | 61 | 未披露 | 未持股 | 2017-03-29 |
董事简历
中英对照 | 中文 | 英文- Stefano Buono
-
Stefano Buono，是AAA的创始人，现任首席执行官、董事。2002年创办AAA之前，他是Centre for Advanced Studies, Research and Development（CRS4）的一名物理学家；他在该公司工作了6年，领导一个工程师团队，从事能源开发、核废料嬗变领域的各种国际性研究项目。他在Physics Nobel Laureate Carlo Rubbia at CERN工作了近10年，这是世界上最大的粒子物理 研究实验室。他积极参与了CERN绝热共振交汇法的开发。他撰写了许多科学论文。1991年，他在意大利都灵的Universita degli Studi di Torino获得物理硕士学位。
Stefano Buono is the Chief Executive Officer, a member of our board of directors, and a founder of AAA. Prior to founding AAA in 2002 Mr. Buono worked as a physicist at the Centre for Advanced Studies, Research and Development, or CRS4. During his six years with CRS4 Mr. Buono headed a team of engineers working on different international research projects in the field of energy production and nuclear waste transmutation. For approximately ten years, he worked with Physics Nobel Laureate Carlo Rubbia at CERN, the world’s largest research laboratory for particle physics. He actively participated in the development of CERN’s Adiabatic Resonance Crossing method. He is the author of numerous scientific papers. Mr. Buono received his master’s degree in physics from the Universita degli Studi di Torino in Turin, Italy in 1991. - Stefano Buono，是AAA的创始人，现任首席执行官、董事。2002年创办AAA之前，他是Centre for Advanced Studies, Research and Development（CRS4）的一名物理学家；他在该公司工作了6年，领导一个工程师团队，从事能源开发、核废料嬗变领域的各种国际性研究项目。他在Physics Nobel Laureate Carlo Rubbia at CERN工作了近10年，这是世界上最大的粒子物理 研究实验室。他积极参与了CERN绝热共振交汇法的开发。他撰写了许多科学论文。1991年，他在意大利都灵的Universita degli Studi di Torino获得物理硕士学位。
- Stefano Buono is the Chief Executive Officer, a member of our board of directors, and a founder of AAA. Prior to founding AAA in 2002 Mr. Buono worked as a physicist at the Centre for Advanced Studies, Research and Development, or CRS4. During his six years with CRS4 Mr. Buono headed a team of engineers working on different international research projects in the field of energy production and nuclear waste transmutation. For approximately ten years, he worked with Physics Nobel Laureate Carlo Rubbia at CERN, the world’s largest research laboratory for particle physics. He actively participated in the development of CERN’s Adiabatic Resonance Crossing method. He is the author of numerous scientific papers. Mr. Buono received his master’s degree in physics from the Universita degli Studi di Torino in Turin, Italy in 1991.
- Christian Merle
-
Christian Merle，自2014年6月以来，他一直担任我们董事会的成员。他是Merle & Partners公司的管理合伙人。2014年创立Merle & Partners公司之前，他曾担任Banque Espirito Santo公司的首席执行官（2007年至2013年）、Gimar & Cie公司的管理合伙人（2003年至2007年）、Banca Intesa公司的首席执行官（1998年至2003年）。加入Banca Intesa公司之前，他曾担任Credit Agricole公司的多种职务，包括Credit Agricole Indosuez公司的执行副总裁。他也曾担任法国财政部的多种职务，包括美国首席代表（从1987年到1990年）。他于1974年获得the Institut d’Etudes Politiques de Paris（位于法国巴黎）的学士学位，还于1975年获得the Université de Paris I-Panthéon Sorbonne（位于法国巴黎）的经济学硕士学位。
Christian Merle became a member of our board of directors in June 2014. Mr. Merle is the Managing Partner of Merle & Partners. Prior to founding Merle & Partners in 2014 Mr. Merle was the Chief Executive Officer of Banque Espirito Santo from 2007 to 2013 the Managing Partner of Gimar & Cie from 2003 to 2007 and the Chief Executive Officer of Banca Intesa from 1998 to 2003. Prior to joining Banca Intesa, he served in various roles at Credit Agricole, including as the Executive Vice President of Credit Agricole Indosuez. He also served in various roles in the French Treasury, including the Chief Representative in the United States from 1987 to 1990. He received his undergraduate degree from the Institut d’Etudes Politiques de Paris in 1974 and a master’s degree in economics from the Universite de Paris I-Pantheon Sorbonne in 1975 both in Paris, France. - Christian Merle，自2014年6月以来，他一直担任我们董事会的成员。他是Merle & Partners公司的管理合伙人。2014年创立Merle & Partners公司之前，他曾担任Banque Espirito Santo公司的首席执行官（2007年至2013年）、Gimar & Cie公司的管理合伙人（2003年至2007年）、Banca Intesa公司的首席执行官（1998年至2003年）。加入Banca Intesa公司之前，他曾担任Credit Agricole公司的多种职务，包括Credit Agricole Indosuez公司的执行副总裁。他也曾担任法国财政部的多种职务，包括美国首席代表（从1987年到1990年）。他于1974年获得the Institut d’Etudes Politiques de Paris（位于法国巴黎）的学士学位，还于1975年获得the Université de Paris I-Panthéon Sorbonne（位于法国巴黎）的经济学硕士学位。
- Christian Merle became a member of our board of directors in June 2014. Mr. Merle is the Managing Partner of Merle & Partners. Prior to founding Merle & Partners in 2014 Mr. Merle was the Chief Executive Officer of Banque Espirito Santo from 2007 to 2013 the Managing Partner of Gimar & Cie from 2003 to 2007 and the Chief Executive Officer of Banca Intesa from 1998 to 2003. Prior to joining Banca Intesa, he served in various roles at Credit Agricole, including as the Executive Vice President of Credit Agricole Indosuez. He also served in various roles in the French Treasury, including the Chief Representative in the United States from 1987 to 1990. He received his undergraduate degree from the Institut d’Etudes Politiques de Paris in 1974 and a master’s degree in economics from the Universite de Paris I-Pantheon Sorbonne in 1975 both in Paris, France.
- Leopoldo Zambeletti
-
Leopoldo Zambeletti，2014年6月，成为本公司董事。他目前是生命科学行业的一名独立财务顾问，已为多家企业提供企业财务事项方面的咨询服务，其中包括建议Nogra Pharma进行史上最大的技术授出业务，向Celgene授权化合物的开发。成为一名顾问之前，2007-2012，他曾担任Credit Suisse的董事总经理兼欧洲、印度、中东、北美保健行业投资银行业务总监，以及Credit Suisse的董事总经理、投资银行超高净值部总监。1994-2007，他在J.P. Morgan担任过多个职务，其中包括保健行业投资银行业务总监。1992年，他在意大利米兰的Università Commerciale Luigi Bocconi获得工商管理学士学位。他现为Nogra Pharma、Summit Therapeutics Qardio、Dignity Biosciences、Faron Pharmaceuticals的董事，以及Saint Barts and the London Charity的受托人。
Leopoldo Zambeletti joined our board of directors on April 19 2018. During a 19 year career as an investment banker, Mr. Zambeletti led the European Healthcare Investment Banking team at JPMorgan for eight years from April 1999 to April 2007 before taking up the same position at Credit Suisse for a further five years from September 2112 to November 2012. Since 2013 he has been an independent strategic advisor to life science companies on merger and acquisitions, out-licensing deals and financing strategy. He is a non-executive director of, Qardio Inc., Summit Therapeutics plc, Nogra Pharma Limited, Faron Pharmaceuticals OY and DS Biopharma Limited. Mr. Zambeletti started his career at KPMG as an auditor. Mr. Zambeletti received a B.A. in Business from Bocconi University in Milan, Italy. He serves as a trustee to Barts and the London Charity, which helps to fund the hospitals of the Barts NHS Trust including St Bartholomew, the Royal London and the London Chest Hospitals. He is the founder of the cultural initiative 5x5 Italy. - Leopoldo Zambeletti，2014年6月，成为本公司董事。他目前是生命科学行业的一名独立财务顾问，已为多家企业提供企业财务事项方面的咨询服务，其中包括建议Nogra Pharma进行史上最大的技术授出业务，向Celgene授权化合物的开发。成为一名顾问之前，2007-2012，他曾担任Credit Suisse的董事总经理兼欧洲、印度、中东、北美保健行业投资银行业务总监，以及Credit Suisse的董事总经理、投资银行超高净值部总监。1994-2007，他在J.P. Morgan担任过多个职务，其中包括保健行业投资银行业务总监。1992年，他在意大利米兰的Università Commerciale Luigi Bocconi获得工商管理学士学位。他现为Nogra Pharma、Summit Therapeutics Qardio、Dignity Biosciences、Faron Pharmaceuticals的董事，以及Saint Barts and the London Charity的受托人。
- Leopoldo Zambeletti joined our board of directors on April 19 2018. During a 19 year career as an investment banker, Mr. Zambeletti led the European Healthcare Investment Banking team at JPMorgan for eight years from April 1999 to April 2007 before taking up the same position at Credit Suisse for a further five years from September 2112 to November 2012. Since 2013 he has been an independent strategic advisor to life science companies on merger and acquisitions, out-licensing deals and financing strategy. He is a non-executive director of, Qardio Inc., Summit Therapeutics plc, Nogra Pharma Limited, Faron Pharmaceuticals OY and DS Biopharma Limited. Mr. Zambeletti started his career at KPMG as an auditor. Mr. Zambeletti received a B.A. in Business from Bocconi University in Milan, Italy. He serves as a trustee to Barts and the London Charity, which helps to fund the hospitals of the Barts NHS Trust including St Bartholomew, the Royal London and the London Chest Hospitals. He is the founder of the cultural initiative 5x5 Italy.
- Kapil Dhingra
-
Kapil Dhingra，他于2014年3月成为Advanced Accelerator Applications董事会的成员。他曾创立KAPital Consulting公司（医疗咨询公司），并担任主管，加入AAA公司之前，他曾从事肿瘤临床研究和药物开发25年以上。他曾任职Hoffman-La Roche公司9年，在那里他曾担任多种职务，包括副总裁、肿瘤疾病生物学领导团队主管，以及肿瘤临床开发主管。此前，他曾担任Eli Lilly and Company的高级临床研究医生。他专注于内科医学和医学肿瘤学。他持有the All India Institute of Medical Sciences（位于印度新德里）的医学硕士学位，随后在Lincoln Medical and Mental Health Center（位于纽约市） 、New York Medical College（位于纽约瓦尔哈拉）进行内科实习。他也是Emory大学School of Medicine（位于乔治亚州亚特兰大）的血液学/肿瘤学研究员。
Kapil Dhingra,has served as Chairperson of board and as a non-executive director since January 2021. He has served as Managing Member of KAPital Consulting, LLC, which he also co-founded, since 2008. Dr. Dhingra currently serves on the boards of directors of several publicly traded and privately held companies, including Black Diamond Therapeutics, Inc. since January 2021, Replimune Group since July 2017, Median Technologies since June 2017, Kirilys Therapeutics since March 2021, Servier since January 2022, and CARGO Therapeutics since April 2024. He also served on the board of directors at Mariana Oncology from January 2022 to May 2024, at Autolus Therapeutics from August 2014 to December 2023 and Five Prime Therapeutics from December 2015 to April 2021. Dr. Dhingra previously served as Vice President, Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development at Hoffman-La Roche from May 1999 to August 2008. He received a M.B.B.S. from the All India Institute of Medical Sciences. - Kapil Dhingra，他于2014年3月成为Advanced Accelerator Applications董事会的成员。他曾创立KAPital Consulting公司（医疗咨询公司），并担任主管，加入AAA公司之前，他曾从事肿瘤临床研究和药物开发25年以上。他曾任职Hoffman-La Roche公司9年，在那里他曾担任多种职务，包括副总裁、肿瘤疾病生物学领导团队主管，以及肿瘤临床开发主管。此前，他曾担任Eli Lilly and Company的高级临床研究医生。他专注于内科医学和医学肿瘤学。他持有the All India Institute of Medical Sciences（位于印度新德里）的医学硕士学位，随后在Lincoln Medical and Mental Health Center（位于纽约市） 、New York Medical College（位于纽约瓦尔哈拉）进行内科实习。他也是Emory大学School of Medicine（位于乔治亚州亚特兰大）的血液学/肿瘤学研究员。
- Kapil Dhingra,has served as Chairperson of board and as a non-executive director since January 2021. He has served as Managing Member of KAPital Consulting, LLC, which he also co-founded, since 2008. Dr. Dhingra currently serves on the boards of directors of several publicly traded and privately held companies, including Black Diamond Therapeutics, Inc. since January 2021, Replimune Group since July 2017, Median Technologies since June 2017, Kirilys Therapeutics since March 2021, Servier since January 2022, and CARGO Therapeutics since April 2024. He also served on the board of directors at Mariana Oncology from January 2022 to May 2024, at Autolus Therapeutics from August 2014 to December 2023 and Five Prime Therapeutics from December 2015 to April 2021. Dr. Dhingra previously served as Vice President, Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development at Hoffman-La Roche from May 1999 to August 2008. He received a M.B.B.S. from the All India Institute of Medical Sciences.
- Francois Nader
-
Francois Nader自2008年3月一直担任NPS总裁兼首席执行官。他于2006年6月加盟 NPS，担任执行副总裁兼首席运营官直至2008年3月。加入NPS之前，他曾任Care Capital, LLC风险投资合伙人，在那里他从2005年7月至2006年6月担任其临床开发投资部首席医疗官。从2000年到2004年，他担任Aventis Pharmaceuticals综合保健市场高级副总裁和北美医学与监管事务高级副总裁。他还在Hoechst Marion Roussel任类似职位，并担任Rhone-Poulenc的Pasteur Vaccines事业部任全球商业运营总监。他是BioNJ的董事会主席，这是一家在新泽西州代表生物技术产业的贸易协会。他是Biotechnology Industry Organization BIO和the New Jersey Chamber of Commerce成员。他也是Trevena, Inc董事及其Compensation Committee主席。他获得St. Joseph University（黎巴嫩）法国国家博士学位和University of Tennessee获得Physician Executive公司管理硕士学位。
Francois Nader,served as President, CEO and Executive Director of NPS Pharmaceuticals from 2008 until 2015, when the company was acquired. During his tenure as CEO, Dr. Nader transformed NPS Pharma into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases. From September 2023 to January 2024, Dr. Nader served as the acting Chief Executive Officer of BenevolentAI while the company conducted a CEO search. Prior to NPS, Dr. Nader was a venture partner at Care Capital. He previously served on Aventis Pharma's North America Leadership Team, holding a number of executive positions in integrated healthcare markets and medical and regulatory affairs. Dr. Nader previously led global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc. He is a senior advisor for Blackstone Life Sciences. Dr. Nader is the former Chairman of BioNJ, New Jersey's biotechnology trade organization, and previously served on the board of the Biotechnology Industry Organization,Education:French doctorate in Medicine from St. Joseph University in Lebanon,Physician Executive M.B.A. from the University of Tennessee. - Francois Nader自2008年3月一直担任NPS总裁兼首席执行官。他于2006年6月加盟 NPS，担任执行副总裁兼首席运营官直至2008年3月。加入NPS之前，他曾任Care Capital, LLC风险投资合伙人，在那里他从2005年7月至2006年6月担任其临床开发投资部首席医疗官。从2000年到2004年，他担任Aventis Pharmaceuticals综合保健市场高级副总裁和北美医学与监管事务高级副总裁。他还在Hoechst Marion Roussel任类似职位，并担任Rhone-Poulenc的Pasteur Vaccines事业部任全球商业运营总监。他是BioNJ的董事会主席，这是一家在新泽西州代表生物技术产业的贸易协会。他是Biotechnology Industry Organization BIO和the New Jersey Chamber of Commerce成员。他也是Trevena, Inc董事及其Compensation Committee主席。他获得St. Joseph University（黎巴嫩）法国国家博士学位和University of Tennessee获得Physician Executive公司管理硕士学位。
- Francois Nader,served as President, CEO and Executive Director of NPS Pharmaceuticals from 2008 until 2015, when the company was acquired. During his tenure as CEO, Dr. Nader transformed NPS Pharma into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases. From September 2023 to January 2024, Dr. Nader served as the acting Chief Executive Officer of BenevolentAI while the company conducted a CEO search. Prior to NPS, Dr. Nader was a venture partner at Care Capital. He previously served on Aventis Pharma's North America Leadership Team, holding a number of executive positions in integrated healthcare markets and medical and regulatory affairs. Dr. Nader previously led global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc. He is a senior advisor for Blackstone Life Sciences. Dr. Nader is the former Chairman of BioNJ, New Jersey's biotechnology trade organization, and previously served on the board of the Biotechnology Industry Organization,Education:French doctorate in Medicine from St. Joseph University in Lebanon,Physician Executive M.B.A. from the University of Tennessee.
- Claudio Costamagna
-
Claudio Costamagna，他是CC e Soci S.r.l（他于2007年6月创立的金融顾问公司）主席。他在投资银行业工作18年，有着丰富的经验，在The Goldman Sachs Group, Inc.担任过多个职务直到2006年4月，最终在2004年12月至2006年3月担任欧洲、中东和非洲投资银行部门主席。他是Luxottica Group S.p.A人力资源委员会董事兼主席，还是Salini Impregilo Group董事会董事兼主席，这些都是意大利证券交易所上市公司。他是Bulgari SpA, Autogrill S.p.A., DeA Capital S.p.A。 以及 IL Sole 24 Ore S.p.A。这些大利证券交易所上市公司前董事。他在The Goldman Sachs Group18年的职业生涯中，最终在2004年至2006年担任欧洲、中东和非洲投资银行部门主席。他的资本市场、并购和投资银行业的经验对公司的商业和工业有着重要意义，他曾是The Goldman Sachs Group 和 CC e Soci.Experience高管，领导The Goldman Sachs Group在欧洲、中东和非洲投资银行部门。他是一些非美国上市公司董事或主席，包括目前的Luxottica Group S.p.A董事以及Salini Impregilo Group董事，这些公司都是意大利证券交易所上市公司， DeA Capital S.p.A., IL Sole 24 Ore S.p.A., Bulgari SpA 及 Autogrill S.p.A前主席或董事，这些都是，或曾是意大利证券交易所上市公司。他还是一些非美国私营公司董事或主席，包括Virgin Group Holding Limited, Advanced Accelerator Applications AAA S.A., Virtual B SIM 以及 CC e Soci。他也是一些非上市教育和慈善机构理事或董事，包括Universita L. Bocconi国际顾问委员会成员。
Claudio Costamagna is Chairman of CC e Soci S.r.l., a financial advisory firm he founded in June 2007. Mr. Costamagna has extensive experience in investment banking having served for 18 years, until April 2006 in various positions with The Goldman Sachs Group, Inc., culminating as Chairman of the Investment Banking Division in Europe, the Middle East and Africa from December 2004 to March 2006. - Claudio Costamagna，他是CC e Soci S.r.l（他于2007年6月创立的金融顾问公司）主席。他在投资银行业工作18年，有着丰富的经验，在The Goldman Sachs Group, Inc.担任过多个职务直到2006年4月，最终在2004年12月至2006年3月担任欧洲、中东和非洲投资银行部门主席。他是Luxottica Group S.p.A人力资源委员会董事兼主席，还是Salini Impregilo Group董事会董事兼主席，这些都是意大利证券交易所上市公司。他是Bulgari SpA, Autogrill S.p.A., DeA Capital S.p.A。 以及 IL Sole 24 Ore S.p.A。这些大利证券交易所上市公司前董事。他在The Goldman Sachs Group18年的职业生涯中，最终在2004年至2006年担任欧洲、中东和非洲投资银行部门主席。他的资本市场、并购和投资银行业的经验对公司的商业和工业有着重要意义，他曾是The Goldman Sachs Group 和 CC e Soci.Experience高管，领导The Goldman Sachs Group在欧洲、中东和非洲投资银行部门。他是一些非美国上市公司董事或主席，包括目前的Luxottica Group S.p.A董事以及Salini Impregilo Group董事，这些公司都是意大利证券交易所上市公司， DeA Capital S.p.A., IL Sole 24 Ore S.p.A., Bulgari SpA 及 Autogrill S.p.A前主席或董事，这些都是，或曾是意大利证券交易所上市公司。他还是一些非美国私营公司董事或主席，包括Virgin Group Holding Limited, Advanced Accelerator Applications AAA S.A., Virtual B SIM 以及 CC e Soci。他也是一些非上市教育和慈善机构理事或董事，包括Universita L. Bocconi国际顾问委员会成员。
- Claudio Costamagna is Chairman of CC e Soci S.r.l., a financial advisory firm he founded in June 2007. Mr. Costamagna has extensive experience in investment banking having served for 18 years, until April 2006 in various positions with The Goldman Sachs Group, Inc., culminating as Chairman of the Investment Banking Division in Europe, the Middle East and Africa from December 2004 to March 2006.
- Steve Gannon
-
Steve Gannon于2014年6月成为董事会成员。他是Aptalis Pharma Inc.的一位高级副总裁兼首席财务总监及财务主管，直到2014年2月它被卖给了Forest Laboratories。2006年加入Aptalis Pharma之前，1999年至2006年Gannon先生担任Cryocath Technologies Inc.的首席财务官；1996年至1999年，担任 Astrazeneca Canada Inc.研究部的财务和行政总监；1989年至1995年，在Mallinckrodt Medical Inc.加拿大的业务担任首席财务官。他于1983年获得加拿大蒙特利尔 Concordia University的会计和业务系统的商学士学位，1995年完成了加拿大安大略省业务Richard Ivey School of Business at the University of Western Ontario的执行课程。自1985年以来，他一直是一名注册会计师。
Steve Gannon has served as a member of our board of directors since January 2020. Mr. Gannon has served on the board of directors of Xenon Pharmaceutics Inc., a biotechnology company, since May 2015 and the board of directors of enGene Inc., a biotechnology company, since February 2017. From June 2014 to March 2018 Mr. Gannon served on the board of directors of Advanced Accelerator Applications SA, a healthcare company acquired by Novartis in January 2018. Mr. Gannon was Chief Financial Officer, Senior Vice President of Finance and Treasurer at Aptalis Pharma Inc. until February 2014 after which it was sold to Forest Laboratories. Prior to joining Aptalis in 2006 Mr. Gannon served as the Chief Financial Officer for Cryocath Technologies Inc. from 1999 to 2006 as the Director of Finance and Administration of the Research Division of AstraZeneca Canada Inc. from 1996 to 1999 and as the Chief Financial Officer of Mallinckrodt Medical Inc.’s Canadian operations from 1989 to 1995. He received a BComm in Accounting and Business Systems from Concordia University in Montreal, Canada in 1983 and completed the Executive Program at the Richard Ivey School of Business at the University of Western Ontario in Ontario, Canada in 1995. He has been a Chartered Accountant since 1985. - Steve Gannon于2014年6月成为董事会成员。他是Aptalis Pharma Inc.的一位高级副总裁兼首席财务总监及财务主管，直到2014年2月它被卖给了Forest Laboratories。2006年加入Aptalis Pharma之前，1999年至2006年Gannon先生担任Cryocath Technologies Inc.的首席财务官；1996年至1999年，担任 Astrazeneca Canada Inc.研究部的财务和行政总监；1989年至1995年，在Mallinckrodt Medical Inc.加拿大的业务担任首席财务官。他于1983年获得加拿大蒙特利尔 Concordia University的会计和业务系统的商学士学位，1995年完成了加拿大安大略省业务Richard Ivey School of Business at the University of Western Ontario的执行课程。自1985年以来，他一直是一名注册会计师。
- Steve Gannon has served as a member of our board of directors since January 2020. Mr. Gannon has served on the board of directors of Xenon Pharmaceutics Inc., a biotechnology company, since May 2015 and the board of directors of enGene Inc., a biotechnology company, since February 2017. From June 2014 to March 2018 Mr. Gannon served on the board of directors of Advanced Accelerator Applications SA, a healthcare company acquired by Novartis in January 2018. Mr. Gannon was Chief Financial Officer, Senior Vice President of Finance and Treasurer at Aptalis Pharma Inc. until February 2014 after which it was sold to Forest Laboratories. Prior to joining Aptalis in 2006 Mr. Gannon served as the Chief Financial Officer for Cryocath Technologies Inc. from 1999 to 2006 as the Director of Finance and Administration of the Research Division of AstraZeneca Canada Inc. from 1996 to 1999 and as the Chief Financial Officer of Mallinckrodt Medical Inc.’s Canadian operations from 1989 to 1995. He received a BComm in Accounting and Business Systems from Concordia University in Montreal, Canada in 1983 and completed the Executive Program at the Richard Ivey School of Business at the University of Western Ontario in Ontario, Canada in 1995. He has been a Chartered Accountant since 1985.
- Yvonne Greenstreet
-
Yvonne Greenstreet，在2010到2013年间是Pfizer的高级副总裁和药物开发主管。加入Pfizer之前，她从1992年到2010年在GlaxoSmithKline担任各种角色，包括欧洲的首席医疗官和战略首领。她服务于the Bill and Melinda Gates Foundation的咨询委员会（Advisory Board），是 Pacira的董事会成员。1990年她在英国伦敦的London大学医院完成了她的医疗培训，在1985年获得英国利兹的Leeds大学的医学学士学位（MBChB）。她随后于1991年在法国枫丹白露的欧洲工商管理学院（INSEAD）完成工商管理硕士学位。
Yvonne Greenstreet,has served as a director since March 2014. Dr. Greenstreet has served as Executive Vice President and Chief Operating Officer of Alnylam Pharmaceuticals, a leading RNAi therapeutics company, since September 2016. Previously, Dr. Greenstreet served as the Senior Vice President and Head of Medicines Development at Pfizer Inc. "Pfizer", a multinational pharmaceutical company based in New York, from December 2010 to November 2013. Prior to joining Pfizer, Dr. Greenstreet worked for 18 years at GlaxoSmithKline plc ("GSK"), a multinational pharmaceutical, biologics, vaccines and consumer healthcare company based in London, where she served in various positions, most recently as Senior Vice President and Chief of Strategy for Research and Development and as a member of GSK's corporate executive investment committee. Dr. Greenstreet currently serves on the Advisory Board of the Bill and Melinda Gates Foundation, and also currently serves on the board of directors of Indivior PLC, and Moelis and Company. Dr. Greenstreet previously served as a director of Molecular Insight Pharmaceuticals, Inc. from 2008 to 2010. She trained as a physician and earned her medical degree from Leeds University in the United Kingdom and her M.B.A. from INSEAD, France. - Yvonne Greenstreet，在2010到2013年间是Pfizer的高级副总裁和药物开发主管。加入Pfizer之前，她从1992年到2010年在GlaxoSmithKline担任各种角色，包括欧洲的首席医疗官和战略首领。她服务于the Bill and Melinda Gates Foundation的咨询委员会（Advisory Board），是 Pacira的董事会成员。1990年她在英国伦敦的London大学医院完成了她的医疗培训，在1985年获得英国利兹的Leeds大学的医学学士学位（MBChB）。她随后于1991年在法国枫丹白露的欧洲工商管理学院（INSEAD）完成工商管理硕士学位。
- Yvonne Greenstreet,has served as a director since March 2014. Dr. Greenstreet has served as Executive Vice President and Chief Operating Officer of Alnylam Pharmaceuticals, a leading RNAi therapeutics company, since September 2016. Previously, Dr. Greenstreet served as the Senior Vice President and Head of Medicines Development at Pfizer Inc. "Pfizer", a multinational pharmaceutical company based in New York, from December 2010 to November 2013. Prior to joining Pfizer, Dr. Greenstreet worked for 18 years at GlaxoSmithKline plc ("GSK"), a multinational pharmaceutical, biologics, vaccines and consumer healthcare company based in London, where she served in various positions, most recently as Senior Vice President and Chief of Strategy for Research and Development and as a member of GSK's corporate executive investment committee. Dr. Greenstreet currently serves on the Advisory Board of the Bill and Melinda Gates Foundation, and also currently serves on the board of directors of Indivior PLC, and Moelis and Company. Dr. Greenstreet previously served as a director of Molecular Insight Pharmaceuticals, Inc. from 2008 to 2010. She trained as a physician and earned her medical degree from Leeds University in the United Kingdom and her M.B.A. from INSEAD, France.
高管简历
中英对照 | 中文 | 英文- Stefano Buono
Stefano Buono，是AAA的创始人，现任首席执行官、董事。2002年创办AAA之前，他是Centre for Advanced Studies, Research and Development（CRS4）的一名物理学家；他在该公司工作了6年，领导一个工程师团队，从事能源开发、核废料嬗变领域的各种国际性研究项目。他在Physics Nobel Laureate Carlo Rubbia at CERN工作了近10年，这是世界上最大的粒子物理 研究实验室。他积极参与了CERN绝热共振交汇法的开发。他撰写了许多科学论文。1991年，他在意大利都灵的Universita degli Studi di Torino获得物理硕士学位。
Stefano Buono is the Chief Executive Officer, a member of our board of directors, and a founder of AAA. Prior to founding AAA in 2002 Mr. Buono worked as a physicist at the Centre for Advanced Studies, Research and Development, or CRS4. During his six years with CRS4 Mr. Buono headed a team of engineers working on different international research projects in the field of energy production and nuclear waste transmutation. For approximately ten years, he worked with Physics Nobel Laureate Carlo Rubbia at CERN, the world’s largest research laboratory for particle physics. He actively participated in the development of CERN’s Adiabatic Resonance Crossing method. He is the author of numerous scientific papers. Mr. Buono received his master’s degree in physics from the Universita degli Studi di Torino in Turin, Italy in 1991.- Stefano Buono，是AAA的创始人，现任首席执行官、董事。2002年创办AAA之前，他是Centre for Advanced Studies, Research and Development（CRS4）的一名物理学家；他在该公司工作了6年，领导一个工程师团队，从事能源开发、核废料嬗变领域的各种国际性研究项目。他在Physics Nobel Laureate Carlo Rubbia at CERN工作了近10年，这是世界上最大的粒子物理 研究实验室。他积极参与了CERN绝热共振交汇法的开发。他撰写了许多科学论文。1991年，他在意大利都灵的Universita degli Studi di Torino获得物理硕士学位。
- Stefano Buono is the Chief Executive Officer, a member of our board of directors, and a founder of AAA. Prior to founding AAA in 2002 Mr. Buono worked as a physicist at the Centre for Advanced Studies, Research and Development, or CRS4. During his six years with CRS4 Mr. Buono headed a team of engineers working on different international research projects in the field of energy production and nuclear waste transmutation. For approximately ten years, he worked with Physics Nobel Laureate Carlo Rubbia at CERN, the world’s largest research laboratory for particle physics. He actively participated in the development of CERN’s Adiabatic Resonance Crossing method. He is the author of numerous scientific papers. Mr. Buono received his master’s degree in physics from the Universita degli Studi di Torino in Turin, Italy in 1991.
- Heinz Mausli
Heinz Mausli，现任首席财务官；2008-2014，担任本公司董事。他于2003年加入AAA。他还是AAA一些子公司的董事。加入AAA之前，1996-2001，他是Accenture的管理顾问；1995-1996，担任Gemini Consulting的管理顾问。1988年，他在瑞士St. Gallen的University of St. Gallen获得硕士学位；1994年，在纽约州纽约市Columbia Business School获得工商管理硕士学位。
Heinz Mausli is a Director and a member of the Audit Committee and Compensation Committee, serving on the Board of Directors since June 2020. He is also a member of the Board of Directors of Inventiva SA. He served on the Board of Directors and as the Chairperson of the Audit Committee of Progenics until its acquisition by the Company. Mr. Musli is the former Chief Financial Officer of Advanced Accelerator Applications S.A., previously serving on its board and also on the executive team that managed its integration into Novartis AG after helping it grow into a global leader within its field. Mr. Musli previously worked as a management consultant for a number of strategy projects in both Europe and the United States for Accenture and Gemini Consulting, as well as independently.- Heinz Mausli，现任首席财务官；2008-2014，担任本公司董事。他于2003年加入AAA。他还是AAA一些子公司的董事。加入AAA之前，1996-2001，他是Accenture的管理顾问；1995-1996，担任Gemini Consulting的管理顾问。1988年，他在瑞士St. Gallen的University of St. Gallen获得硕士学位；1994年，在纽约州纽约市Columbia Business School获得工商管理硕士学位。
- Heinz Mausli is a Director and a member of the Audit Committee and Compensation Committee, serving on the Board of Directors since June 2020. He is also a member of the Board of Directors of Inventiva SA. He served on the Board of Directors and as the Chairperson of the Audit Committee of Progenics until its acquisition by the Company. Mr. Musli is the former Chief Financial Officer of Advanced Accelerator Applications S.A., previously serving on its board and also on the executive team that managed its integration into Novartis AG after helping it grow into a global leader within its field. Mr. Musli previously worked as a management consultant for a number of strategy projects in both Europe and the United States for Accenture and Gemini Consulting, as well as independently.
- Gerard Ber
Gerard Ber，现任首席运营官；2002-2004，担任本公司董事。他于2002年加入AAA。此前，2000-2002，他是 OM Pharma的西欧地区总监；1994-2000，担任CIS Medipro的总监、营销与商务总监；1984-1994，在CIS Bio International担任过各种管理职务。他还是AAA一些子公司的董事。1983年，1984年，他在法国Grenoble的Université Scientifique et Médicale de Grenoble分别获得药剂学博士学位、食品高级研究硕士学位；1984年，在法国巴黎的Institut de Pharmacie Industrielle de Paris获得营销与国际商务学位。
Gerard Ber is a Director and a member of the Science and Technology Committee, serving on the Board since June 2020. Dr. Ber is also a member of the Board of Y-mAbs Therapeutics, Inc. He served on the Board of Directors of Progenics until its acquisition by the Company. Dr. Ber was also the Co-Founder and former Chief Operating Officer of Advanced Accelerator Applications S.A. until its acquisition by Novartis AG.- Gerard Ber，现任首席运营官；2002-2004，担任本公司董事。他于2002年加入AAA。此前，2000-2002，他是 OM Pharma的西欧地区总监；1994-2000，担任CIS Medipro的总监、营销与商务总监；1984-1994，在CIS Bio International担任过各种管理职务。他还是AAA一些子公司的董事。1983年，1984年，他在法国Grenoble的Université Scientifique et Médicale de Grenoble分别获得药剂学博士学位、食品高级研究硕士学位；1984年，在法国巴黎的Institut de Pharmacie Industrielle de Paris获得营销与国际商务学位。
- Gerard Ber is a Director and a member of the Science and Technology Committee, serving on the Board since June 2020. Dr. Ber is also a member of the Board of Y-mAbs Therapeutics, Inc. He served on the Board of Directors of Progenics until its acquisition by the Company. Dr. Ber was also the Co-Founder and former Chief Operating Officer of Advanced Accelerator Applications S.A. until its acquisition by Novartis AG.
- Claude Hariton
Claude Hariton，2014年2月加入AAA，担任临床开发总监。过去的25年里，他在瑞士、加拿大、澳大利亚、德国、西班牙、英国的生物技术及制药公司担任过多个高级职务；最近的任职是Mayne Pharma的副总裁、监管事务全球总监；Aeterna-Zentaris的临床与监管事务副总裁、首席医学官；Fresenius 科学事务副总裁；ISDIN全球研发副总裁。1984年，他在法国马赛的University of Sciences获得神经科学博士学位，在法国马赛的INSERM U278完成博士后研究工作；1988年，在法国马赛的University of Medicine 获得药理学博士学位，同时领导瑞士Ciba Geigy、Novartis的药物开发；1998年，被School of Medicine任命为副教授。
Claude Hariton joined AAA in February 2014 as Head of Clinical Development. He was appointed Global Head of Research and Development in January 2016. Over the last 25 years, he has held senior positions in biotechnology and pharmaceutical companies in Switzerland, Canada, Australia, Germany, Spain and the United Kingdom, with his most recent positions including Vice President, Global Head of Regulatory Affairs at Mayne Pharma, Vice President, Clinical and Regulatory Affairs and Chief Medical Officer at Aeterna-Zentaris, Vice President, Scientific Affairs at Fresenius and Vice President, Global Head of R&D at ISDIN. Dr. Hariton received his PhD in neuroscience from the University of Sciences in Marseille, France in 1984 and conducted postdoctoral research at INSERM U278 also in Marseille, France. He received his DSc in Pharmacology from the University of Medicine in Marseille, France in 1988 while leading drug development at Ciba Geigy and Novartis in Switzerland, and was appointed Associate Professor at the School of Medicine in Marseille, France in 1998.- Claude Hariton，2014年2月加入AAA，担任临床开发总监。过去的25年里，他在瑞士、加拿大、澳大利亚、德国、西班牙、英国的生物技术及制药公司担任过多个高级职务；最近的任职是Mayne Pharma的副总裁、监管事务全球总监；Aeterna-Zentaris的临床与监管事务副总裁、首席医学官；Fresenius 科学事务副总裁；ISDIN全球研发副总裁。1984年，他在法国马赛的University of Sciences获得神经科学博士学位，在法国马赛的INSERM U278完成博士后研究工作；1988年，在法国马赛的University of Medicine 获得药理学博士学位，同时领导瑞士Ciba Geigy、Novartis的药物开发；1998年，被School of Medicine任命为副教授。
- Claude Hariton joined AAA in February 2014 as Head of Clinical Development. He was appointed Global Head of Research and Development in January 2016. Over the last 25 years, he has held senior positions in biotechnology and pharmaceutical companies in Switzerland, Canada, Australia, Germany, Spain and the United Kingdom, with his most recent positions including Vice President, Global Head of Regulatory Affairs at Mayne Pharma, Vice President, Clinical and Regulatory Affairs and Chief Medical Officer at Aeterna-Zentaris, Vice President, Scientific Affairs at Fresenius and Vice President, Global Head of R&D at ISDIN. Dr. Hariton received his PhD in neuroscience from the University of Sciences in Marseille, France in 1984 and conducted postdoctoral research at INSERM U278 also in Marseille, France. He received his DSc in Pharmacology from the University of Medicine in Marseille, France in 1988 while leading drug development at Ciba Geigy and Novartis in Switzerland, and was appointed Associate Professor at the School of Medicine in Marseille, France in 1998.